Dr. Craig Cheifetz is the Regional Dean for the UVA School of Medicine at Inova’s Regional Campus and Inova’s Vice President for Corporate Health Services for which services include: concierge medicine, executive healthcare, occupational health, employee assistance, onsite corporate and government clinics, navigation services and wellness programs. Dr. Cheifetz is a model physician and executive leader who is passionate about providing outstanding and progressive clinical care, education, and innovation to his patients, learners and the community. He and his team have built the metro Washington region’s premier concierge medicine and executive health services practice providing service to nearly 6,000 members and 80 corporations encompassing an additional 2,000 individuals. Dr. Cheifetz has trained over 500 academic and community physician educators in how to become better clinical educators. He has lectured at the national, regional, and local levels in the areas of clinical and health education. In addition to his clinical endeavors in the DC Metro region, for the past 15 years, he has advised hundreds of companies, many of which are Fortune 100 companies, on effective and innovative strategies to optimize their health and wellness related workforce programs.

Dr. Cheifetz graduated medical school from the State University of New York at Buffalo and completed his residency and chief residency at Georgetown University Medical Center. He completed both the Stanford Faculty Development Facilitator’s Program in Clinical Teaching and the Harvard-Macy Program for Leaders in Medical Education. He is the recipient of numerous awards for excellence as a clinician and an educator, including the AAMC distinguished service award, the American College of Physicians Laureate Award, two Golden Apple Teaching Awards from Georgetown for his past contributions to medical student and residency education, and, in 2012 received the Walter J. MacDonald Award for the top young internal medicine physician in the United States.

Dr. Florence Haseltine is a trailblazing medical scientist whose work and career has impacted women’s health globally. After receiving a PhD in Biophysics at MIT and an MD from Albert Einstein College of Medicine, Dr. Haseltine completed residency at Boston Hospital for Women (Brigham & Women’s) then served as Associate Professor for Obstetrics, Gynecology and Pediatrics at Yale University School of Medicine. She and her colleagues at Yale were in the forefront of the science and application of IVF.

Dr. Haseltine was appointed as Director of the Center for Population Research at NIH’s National Institute of Child Health and Human Development, where she was responsible for the creating and overseeing all NICHD grants and programs related to maternal and child health and for training the next generation of researchers in the field of obstetrics and gynecology. During this period, Dr. Haseltine also founded the Society for Women’s Health Research, a non-profit organization that played a critical role in helping women gain access to federally-funded clinical trials. She also founded the Journal of Women’s Health, and co-founded the non-profit Organization for the Study of Sex Differences. In 2019, Dr. Haseltine came out of retirement to build and lead the North Texas Genome Center and to serve as Professor in the College of Nursing and Health Innovation at U. Texas Arlington.

Dr. Haseltine is a member of the National Academy of Medicine, a Fellow of the National Academy of Inventors, and a recipient of the Lifetime Achievement Award for the Health and Dignity of Women and Girls from the Friends of the United National Population Fund.

The Honorable James W. Ziglar is Senior Counsel at the Washington, DC law firm of Van Ness Feldman where he advises clients and colleagues on legal and public policy issues. His prior roles include President and CEO of Cross Match Technologies, a leading global provider of biometric technologies and security solutions Sergeant at Arms of the United States Senate, a position in which he served as the Senate’s chief operating officer, chief protocol officer and chief law enforcement officer. He left his Senate post in 2001 when President George W. Bush appointed him, and he was confirmed unanimously by the U.S. Senate, as Commissioner of the Immigration and Naturalization Service, a position he held until December 2002 when the agency was dissolved, and its missions transferred to the new Department of Homeland Security. Mr. Ziglar has over 55 years of experience in management, finance, law, education, and public policy, spending 17 years as an investment banker on Wall Street and 22 years as a practicing lawyer. He began his legal career as a law clerk to U.S. Supreme Court Justice Harry A. Blackmun. He later was Distinguished Visiting Professor of Law at the George Washington University Law School, and he was a Resident Fellow at Harvard University’s John F. Kennedy School of Government Institute of Politics.

Mr. Ziglar presently serves on the Board of Directors of Integrated Biometrics, Inc. and as a Trustee of the Harry A. Blackmun Scholarship Foundation. His prior Board service includes Forward Industries (FORD; Nasdaq); Migration Policy Institute (Chairman), and Radiation Effects Research Foundation (Japan).

Joel S. Kanter is an investor and business leader whose career includes CEO and executive roles in the financial services industry, board roles in the medtech and other sectors, and significant legislative roles. In addition, Mr. Kanter is passionate about his service on numerous non-profit boards aimed at promoting science, innovation and technology; educational opportunities for all; and, the performing arts.

Early in his career, Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.) where he supported work on the House Judiciary Committee. He later served as Special Assistant to the National Association of Attorneys General and was involved in legislative efforts to reenact the Clean Air Act, the Clean Water Act, and to enact the original Superfund Legislation before becoming Staff Director of the House Rules Committee’s Subcommittee on Legislative Process Chaired by the late Congressman Gillis W. Long (D-La.). Following his public service, Mr. Kanter took on leadership roles as Managing Director, The Investors’ Washington Service, an investment advisory company specializing in providing advice to large institutional clients regarding the impact of federal legislative and regulatory decisions on debt and equity markets, then in 1986 as President of Windy City, Inc., and later as President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (NMS: WNUT) that supported different forms of financing to early-stage and more mature companies. The Company was sold to Tower Hill Capital Group in 1999 in a transaction valued at approximately $400 million. Mr. Kanter Chairs or serves on several early-stage life science company Boards as well as on the Board of the School of Science & Engineering at Tulane University. He is Board Chair of the Black Student Fund in Washington, D.C, as well as Board Co-Chair of the Kennedy Center’s National Committee for The Performing Arts.

The Honorable Dr. Kathie L. Olsen is the Founder and President of KLO International, LLC, a consulting firm in Virginia. Believing research is the core foundation for innovation that will sustain global quality of life and economic vitality, she is dedicated to helping people and organizations succeed in their science and engineering research pursuits. Dr. Olsen served over 20+ years in the federal government in a variety scientific leadership positions, including the Deputy Director and Chief Operating Officer of the National Science Foundation (NSF); Associate Director and Deputy Director for Science of Office of Science and Technology Policy (OSTP), Chief Scientist for NASA and the Acting Associate Administrator for NASA’s Biological and Physical Research Enterprise. In these positions, she led strategic and budget planning and oversaw the development of new research and education priorities and initiatives. Following federal service, Dr. Olsen has served on review and advisory panels for U.S. federal agencies including NIH, NSF, DOD, DHS, as well as foreign governments, international research institutes, professional societies, academia, and UNESCO.
Dr. Olsen earned a Ph.D. in Biology (Neuroscience) from UC-Irvine and her Postdoctoral Fellowship was at Children’s Hospital of Harvard Medical School. Her research on neural and genetic mechanisms underlying development and expression of sex differences in behavior was supported by NIH. Academic positions include Assistant Professor in the Department of Psychiatry and Behavioral Science at the State University of New York-Stony Brook and Adjunct Associate Professor in the Department of Microbiology at the George Washington University, and Affiliate Professor of Neuroscience at the Krasnow Institute for Advanced Study, George Mason University.

Dr. Olsen has received numerous honors and awards in recognition of her service to society, including four honorary doctorates from US universities, the American Institute of Aeronautics and Astronautics (AIAA) Public Service Award, Society for Neuroscience Louise Hanson Marshall Recognition Award for significantly promoting the professional development of women in neuroscience, the NSF Director’s Award of Excellence; the University of California, Irvine Lauds and Laurels Distinguished Alumna Award, and the Norwegian Royal Order of Merit. She is an elected Fellow of the American Association for the Advancement of Science, Fellow of the Association for Women in Science, elected member of the ARCS Foundation, the Explorers Club, and the Cosmos Club.

Leslie Alexandre, DrPH has earned a stellar national reputation as a board director and organizational leader based on her robust experience and lengthy track record of success over a 40-year career in the health care and life science arenas. A two-time CEO, Dr. Alexandre has successfully transformed important public-facing organizations, navigated complex ecosystems, built cross-sector partnerships and leaned into board governance to strengthen performance, amplify impact and grow brand value. A known champion for representation and diversity, she builds inclusive cultures that support participation, collaboration and innovation. She has twice led special board committees in revitalizing governance with new policies and practices that facilitated succession planning, diversity, engagement and productivity.

Most recently Dr. Alexandre served as President, CEO and Board Director at Life Science Washington, where she transformed and revitalized the 501(c)(6) industry association, launched and directed a 501(c)(3) subsidiary (the Life Science Washington Institute) to provide concentrated support for entrepreneurs, and successfully positioned greater Seattle as a top 10 national life science ecosystem. Dr. Alexandre previously served in high visibility leadership positions at the Georgia Cancer Center, North Carolina Biotechnology Center, National Cancer Institute, Oncormed, Inc. (AMEX:ONM), and EDS (NYSE:EDS). In each case her contributions markedly improved organizational effectiveness and impact and increased brand equity. She also amassed a number of legislative accomplishments while serving in senior health policy roles for two U.S. Senators (John Heinz, R-PA and Dave Durenberger, R-MN).

For the past 35 years, Dr. Alexandre has advanced strategic objectives, governance priorities and performance of companies (public and private), government agencies, institutes of higher education and non-profit organizations through her contributions to more than 20 boards and advisory committees. She has been honored with a number of awards, among them the Women of Achievement Award from the General Federation of Women’s Clubs of North Carolina; Academy of Women Inductee (Science and Technology) from the YWCA of the Greater Triangle; and Chairman’s Service Award from the Council for Entrepreneurial Development. She earned her DrPH and MSPH from the UCLA School of Public Health and a BA in Community Health from UC Davis.

The Honorable Dr. Rita Colwell is globally recognized leader in infectious diseases, water, and health. In addition to her academic appointments, Dr. Colwell served as 11th Director of the National Science Foundation, a Senate-confirmed appointment, and Co-chair of the White House’s National Science and Technology Council. In the business arena, Dr. Colwell is Founder of CosmosID, Inc which provides metagenomics services and bioinformatics solutions to identify strains of microbes in complex environments.

Dr. Colwell served as Chairman of the Board of Governors of the American Academy of Microbiology, President of the American Association for the Advancement of Science, Washington Academy of Sciences, and American Society for Microbiology, Sigma Xi National Science Honorary Society, International Union of Microbiological Societies, and American Institute of Biological Sciences. Dr. Colwell is a member of the National Academy of Sciences, Royal Swedish Academy of Sciences, Stockholm, Royal Society of Canada, and Royal Irish Academy, American Academy of Arts and Sciences, and American Philosophical Society.

Dr. Colwell has authored or co-authored 20 books and more than 800 scientific publication and has been awarded 63 honorary degrees from institutions of higher education. She is the recipient of the Order of the Rising Sun, Gold and Silver Star, bestowed by the Emperor of Japan, 2006 National Medal of Science awarded by the President of the United States, the 2010 Stockholm Water Prize awarded by the King of Sweden, 2018 Lee Kuan Yew Water Prize of Singapore, and 2024 Lifetime Achievement Award from the American Society for Microbiology.

Romain Murenzi joined Worcester Polytechnic Institute (WPI) as a full professor of Physics in January 2024. Until November 2023, Professor Murenzi served as the Executive Director of The World Academy of Sciences for the advancement of science in developing countries (TWAS), a UNESCO (United Nations Education and Science Organization) programme unit, overseeing also the administration of Organization for Women in Science for the Developing World (OWSD), and the InterAcademy Partnership (IAP). Murenzi initially joined TWAS in April 2011 for five years. He then spent 14 months at UNESCO, Paris, as the Director of the Division of Science Policy and Capacity Building, and Executive Secretary of International Basic Science Programme (IBSP) before returning to TWAS in 2017.

Previously (2001-2009) he served as Rwanda’s Minister of Education, Science and Technology and Scientific Research and as Minister in the President’s Office in Charge of Science and Technology, and Scientific Research. In 2009 he was a senior scholar at the American Association for the Advancement of Science (AAAS) Center for Science, Technology and Sustainable Development; he served as Director from 2010–2011. Professor Murenzi has led numerous UN advisory groups over the years, including the UN Secretary-General appointment as Chair for the feasibility study of the UN Technology Bank for the Least Developed Countries in November 2014 and to serve on the 10-Member Group to support the Technology Facilitation Mechanism in January 2016 for sustainable development goals (SDGs).

Murenzi served as Principal Investigator for the NSF (National Science Foundation) Center for Theoretical Studies of Physical Systems (CTSPS) at Clark University from 1992 to 2001, and as Chair of the Physics Department. Murenzi holds a Bachelor of Science from the University of Burundi, a Master of Science and a PhD from the Catholic University of Louvain in Belgium, a Master of Law degree in Information Technology and Telecommunication from Strathclyde University in the United Kingdom, and an honorary doctoral degree conferred upon him by the University of Johannesburg.

Valerie Darling is a nationally recognized executive and leader in the biotechnology, pharmaceutical and medical device arenas. She currently serves as Executive Board Member, Chief Business Officer and Chief Revenue Officer at Proteas Bioanalytics and is a Board Member of Sequentify. Over her career, she has built significant revenue streams for Fortune 100 companies, including Johnson and Johnson, Bristol Myers Squibb and Genzyme, along with an array of early stage companies in the medical device and healthIT sectors. In addition to her corporate appointments, Ms. Darling has worked to strengthen corporate management through educational and training programs for Board members. She serves on the Board of Directors of the Private Directors Association and led key Board committees on Nominations and Governance and CEO Succession Planning.

Ms. Darling has been honored for her corporate successes and service to the corporate community with numerous awards, including Market Share Growth Leader at Genzyme (6 years), President’s Club at Bristol Myers Squibb, and Manager of the Region Award at Johnson and Johnson, among many others. In 2023, Nasdaq’s Center for Board Excellence and Equilar included Ms. Darling in its Top 50 Diverse Board Candidates, and in 2023 Private Corporate Directors magazine included her in its Top 20 Directors to Watch list.

Ms. Darling is multi-lingual, including Spanish (native speaker), French and German. She holds a BA in Business Administration and Management from the Universidad Complutense de Madrid (through SUNY) and received a certificate from Santa Clara University Leavey School of Business in Women’s Corporate Board Readiness Program. She currently mentors women in the Corporate Board Readiness Program and serves as an Advisor in the Santa Clara University Black Corporate Board Readiness Program.

Judith Auerbach PhD is an Adjunct Professor in the School of Medicine at the University of California San Francisco and an independent science and policy consultant.   She previously served in leadership positions in governmental and non-governmental agencies and organizations, including the National Institutes of Health Office of AIDS Research (OAR), the White House Office of Science and Technology Policy (OSTP), amfAR-The Foundation for AIDS Research, and San Francisco AIDS Foundation.  Dr. Auerbach received her Ph.D. in Sociology from the University of California Berkeley, and has taught, presented, and published widely in the areas of HIV/AIDS, global public health, social science, public policy, women’s health, and sex and gender.

Dr. Auerbach has served on numerous professional and advisory groups, including, the President’s Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board, the National Advisory Council on Drug Abuse, the Governing Council of the International AIDS Society, and the Women’s Research Initiative on HIV/AIDS Advisory Group. She was an originator of the Campaign for a National AIDS Strategy, which resulted in the first U.S. government-wide strategic plan for HIV/AIDS (2010).  Dr. Auerbach has received numerous awards including the 2014 Feminist-Scholar-Activist Award from the Sex and Gender Section of the American Sociological Association and the 2008 Career Award for Contribution to the Sociology of HIV/AIDS from the Sociology AIDS Network.  In 2022, Dr. Auerbach was elected a lifetime Fellow of the American Association for the Advancement of Science (AAAS).

Dr. Auerbach’s research interests focus on social determinants of health and wellbeing; the relationship between science, program, and policy; and community-engaged research.   As a consultant, she advises about scientific agenda-setting, strategic planning and priority-setting, and linking research and policy; and her clients include government agencies, non-profit and advocacy organizations, industry, and universities.

Dr. Margaret Cary is a senior executive, physician, educator and executive coach who combines broad management and patient care experience in health care, information technology and the media. She has held executive positions in several healthcare organizations and has served on the Colorado State Board of Medical Examiners. She combines her understanding of the critical importance of effective communication, emotional intelligence and leadership and management skills in employee productivity and workplace well-being with practical knowledge of how organizations work. She is a graduate of Georgetown University’s Leadership Coaching Certificate Program and an International Coach Federation-credentialed executive coach.

Dr. Cary holds faculty positions at Georgetown University School of Medicine, where she developed the “Hacking Happiness” course and the University of Colorado Denver Business School, where she is on the Executive Advisory Board for the Center for Health Administration. She co-authored Telemedicine and Telehealth: Principles, Policies, Performance and Pitfalls, a seminal text in telehealth and telemedicine. She is published in the Washington Post, The Future of Coaching, The Examined Life: A Literary Journal of the University of Iowa Carver College of Medicine, TheDoctorWeighsIn.com, MD Magazine, Medical Economics, The Journal of Medical Practice Management and others.

As an executive coach, Dr. Cary’s clients value her honesty, insight, and her ability to help them understand their strengths and how to use them in increasing their management and leadership effectiveness. She works in healthcare, academic medicine, insurance and telecommunications.  Her volunteer activities include coaching TED Fellows, Greater Good Fund Fellows, and managing A Whole New Doctor, an initiative that provides leadership development and executive coaching to medical students to better deal with an increasingly complicated, sometimes hostile, healthcare system.

Gerald Cox MD, PhD has been a drug development specialist in the biotech industry for 24 years and a practicing clinical geneticist at Boston Children’s Hospital for over 30 years. In 2018, he started to provide clinical development expertise on a consulting basis to small companies developing innovative treatments for rare genetic diseases. Dr. Cox began his industry career in 2000 at Genzyme, where he rose to Vice President of Clinical Development for Rare Diseases. During his 16-year tenure at Genzyme and later Sanofi Genzyme, he led the clinical development programs for several lysosomal storage disorders that resulted in the approvals of Aldurazyme® [laronidase] for MPS I in 2003 (worldwide), Elaprase® (idursulfase) for MPS II in 2007 (Japan and Asia-Pacific), Cerdelga® [eliglustat] for Gaucher disease type 1 in 2014 (worldwide), and a label expansion of Cerezyme® [imiglucerase] for Gaucher disease type 3 in 2016 (China). As the interim CMO of CANbridge Pharmaceuticals, he was a major contributor to the approval of Hunterase® (idursulfase beta) for MPS II in China in 2020. He also led the early clinical trials at Genzyme supporting the approvals of Lumizyme® [alglucosidase alfa, initially approved as Myozyme®] in 2006 for infantile Pompe disease, and Xenpozyme [olipudase alfa] for acid sphingomyelinase deficiency (Niemann-Pick type B) in 2022. From 2016-2018, Dr. Cox was CMO at Editas Medicine, where he contributed to the first US IND for an in vivo delivered CRISPR-based medicine, EDIT-101, to treat Leber congenital amaurosis type 10, a genetic cause of blindness in children. He sits on the board of directors or scientific advisory boards of several non-profit patient advocacy groups. Dr. Cox is a board-certified medical geneticist (clinical, biochemical, and molecular) who sees patients part-time at Boston Children’s Hospital, where he was formerly on the full-time staff and completed his pediatrics residency and genetics fellowship training. He is board-certified in clinical, biochemical, and molecular genetics, and is an Instructor in Pediatrics at Harvard Medical School. Dr. Cox received his MD, PhD from the University of California, San Diego in 1989, and a BA in biology magna cum laude from Harvard College in 1980. He has over 100 peer-reviewed publications.

Rich Giersch has extensive expertise in technology commercialization and entrepreneurial ecosystem development. With a career spanning leadership roles in academia, non-profit organizations, and the private sector, he has a proven track record of driving innovation and securing substantial dilutive and non-dilutive funding for high-impact projects.

While in senior leadership positions at two venture capital firms Rich led technology due diligence and mentored portfolio companies in non-dilutive funding acquisition. Then as a senior leader at two R1 universities he developed novel technology commercialization and incubator programs with cross campus faculty and NIH support. Rich understands what it takes to develop technology, launch a company and secure funding.

As program director of multiple US SBA funded FAST grants in both Washington and West Virginia he built statewide SBIR/STTR education and mentoring programs that resulted in millions in awards to first time applicants. Additionally, he built matching grant programs in both those states in partnership with state legislatures and the departments of commerce. He has a long history of building ecosystem partnerships including being a principal investigator for a $3.5 million STTR funded NIH Southeast Accelerator Network, consisting of 24 academic institutions and a small business.

With a career in managing large, multidisciplinary consortia, including his role as Chief Science Officer at Rutgers based Armed Forced Institute for Regenerative Medicine, securing over $75 million in non-dilutive funding commitments at 21 Ventures, founding CEO of Valtari bio, Rich is a formidable force in the innovation and commercialization landscape. His commitment to fostering public/private partnerships and mentoring future leaders, positions him as a valuable asset to organizations seeking to build SBIR/STTR capability, and drive technological and entrepreneurial success.

Kim Laidlaw Oksenberg, MBA, PMI-ACP, started her career working in equity research and high-yield sales and trading. After her time in investment banking, she spent nine years as a private equity investor for a multi-billion dollar family of funds at Bank of New York Mellon. In 2011, she was co-founder and COO of Project Eve, a digital platform helping women launch new businesses and reinvent their careers. For the past several years, she has been doing advisory work for early-stage startups as they launch, raise capital, and scale. In the Spring of 2023, she embarked on a new challenge as an Adjunct Instructor at the University of California at Berkeley, teaching a Product Management course. At the same time, she founded a start-up focused consultancy. Kim earned a BA with honors from the University of Vermont and an MBA with a concentration in Finance from New York University.

Mark L. Rohrbaugh, PhD, JD is an expert in US Government funded intellectual property (IP) under the Bayh-Dole and the Federal Technology Transfer Acts. A 30-year veteran of NIH technology transfer policy and practice, he served as the Senior Advisor for Technology Transfer and Innovation in the NIH Office of the Director on matters involving the extramural (grant and contract) and intramural (internal) research programs and directed the Office of Technology Transfer, which managed the patent and licensing portfolio of inventions from the NIH, FDA and CDC intramural research programs.  Mark is a subject matter expert in government rights to use patented inventions, public-private partnerships, rights in data, SBIR/STTR inventions, drug pricing and march-in, US manufacturing requirements, appeals of the denial or termination of licensing rights, complex negotiations over IP, international issues and agreements involving US patent policy.  Mark has served on the National Science and Technology Council Technology Committee, the White House Office of Science and Technology Policy (OSTP) Lab-to-Market Committee, and the Interagency Working Group for Technology Transfer.  He has represented the US at meetings of the World Health Organization (WHO) and the Organization for Economic Co-operation and Development (OECD).   Prior to joining the NIH, he conducted research at two start-up biotechnology companies. Mark received his PhD in biochemistry and molecular biology from The Pennsylvania State University and a degree in law from the George Washington University.

Sally J. Rockey, PhD is the Chief Executive Officer of Rockey Consulting.  Dr. Rockey has had a noteworthy career in leading the operations of prominent research organizations.  She retired in 2022 as Executive Director of the Foundation for Food and Agriculture Research, a 501(c)(3) supporting private/public partnerships that accelerate innovative research and science in agriculture.  As inaugural Executive Director, she built the organization, saw it through its startup phase, and witnessed its growth into the significant force in the agriculture research community that it is today.  Prior to this role, Dr. Rockey was a leader in federal research, overseeing the administration of the extramural programs in both agriculture and biomedicine. She spent almost twenty years with the U.S. Department of Agriculture where she held several positions within the Cooperative State Research, Education, and Extension Service (now the National Institute of Food and Agriculture) including head of research grants.  From there she spent eleven years with the National Institutes of Health as NIH Deputy Director for Extramural Research where she led the research administration of the world’s largest extramural research program.

Dr. Rockey received her Ph.D. in Entomology from The Ohio State University and did postgraduate work at the University of Wisconsin.  She has devoted her career to improving people’s lives through research and continues this mission today.

Melissa Seldin PhD is an experienced social scientist who brings a unique perspective to her work. Her expertise lies in multifaceted research design and execution and in translating complex concepts into clear, concise language, as well as in grant writing, program evaluation, and building effective data dashboards.  She holds a Ph.D. in Political Science from the Graduate Center of the City University of New York and a B.A. in Political Science from Washington University in St. Louis. Dr. Seldin is based in Pittsburgh, PA.

Dr. Seldin has held diverse positions in R & D.  She led an 8-person team at Synergy Enterprises, a small government contractor, where she managed research, survey, and evaluation projects. During her time there, she significantly increased team task responsibilities through new proposals and contract extensions from $75k to just under $1m. Her background also includes serving as the Research Officer in charge of non-fiscal compliance for University grantees at the Office of Sponsored Programs at the University of the District of Columbia. In this role, she authored approximately 15 to 20 proposals annually for various organizations, such as NIH, NSF, DARPA, DoD, and ED. Additionally, she created, implemented, and managed the responsible conduct of research programs for faculty and students and authored policies on data management and intellectual property.

Outside work, Dr. Seldin is a master ‘s-level competitive rower, an avid mystery reader, and an amateur chef. She also enjoys spending time with her husband, kids, and two dogs.